Brainstorm Cell Therapeutics Inc. (BCLI)
Stock Price:
$5.46 USD
0.02 (0.37%)
Updated December 3, 4:00 PM EST - Market closed
Key Info
| Market Cap |
172.36M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-27.69M |
| Shares Out |
31.15M |
| EPS (ttm) |
-1.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 3 |
| Last Price |
$5.46 |
| Previous Close |
$5.44 |
| Change ($) |
0.02 |
| Change (%) |
0.37% |
| Day's Open |
5.43 |
| Day's Range |
5.05 - 5.49 |
| Day's Volume |
829,535 |
| 52-Week Range |
3.69 - 17.73 |
More Stats
| Market Cap |
172.36M |
| Enterprise Value |
145.05M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
31.15M |
| Float |
n/a |
| EPS (basic) |
-1.05 |
| EPS (diluted) |
-1.02 |
| FCF / Share |
-1.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.42M |
| Short Ratio |
6.78 |
| Short % of Float |
n/a |
| Beta |
0.90 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.38 |
| Revenue |
n/a |
| Operating Income |
-27.86M |
| Net Income |
-27.69M |
| Free Cash Flow |
-31.38M |
| Net Cash |
27.31M |
| Net Cash / Share |
0.87 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-85.98% |
| ROE |
-288.40% |
| ROIC |
1,609.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
0 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$22.50*
(312.09% upside)
Low
20.0
Current: $5.46
High
25.0
Target: 22.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -23.00 | -14.06 | -5.00 | -5.08 | -8.54 | -7.42 | -5.04 | -3.52 | -3.89 | -2.59 |
| Net Income | -23.25 | -13.95 | -4.95 | -4.98 | -8.49 | -9.25 | -4.90 | -3.43 | -3.92 | -2.42 |
| Shares Outstanding | 21.91 | 20.00 | 18.78 | 18.66 | 18.41 | 13.66 | 10.74 | 9.17 | 8.01 | 5.94 |
| Earnings Per Share | -1.06 | -0.70 | -0.26 | -0.27 | -0.46 | -0.68 | -0.46 | -0.30 | -0.45 | -0.45 |
| Operating Cash Flow | -11.25 | -12.39 | -2.36 | -5.86 | -7.41 | -4.49 | -4.05 | -2.94 | -2.22 | -2.07 |
| Capital Expenditures | -0.47 | -0.37 | -0.18 | -0.10 | -0.05 | -0.16 | -0.11 | -0.09 | -0.05 | -0.01 |
| Free Cash Flow | -11.72 | -12.76 | -2.54 | -5.96 | -7.45 | -4.65 | -4.16 | -3.03 | -2.27 | -2.07 |
| Cash & Equivalents | 0.57 | 7.06 | 7.76 | 9.99 | 15.96 | 8.54 | 3.50 | 4.09 | 1.92 | 0.09 |
| Total Debt | 2.37 | - | - | - | - | - | - | - | - | 0.14 |
| Net Cash / Debt | -1.80 | 7.06 | 7.76 | 9.99 | 15.96 | 8.54 | 3.50 | 4.09 | 1.92 | -0.04 |
| Assets | 6.53 | 11.23 | 11.42 | 10.77 | 17.08 | 9.91 | 4.73 | 5.14 | 2.74 | 1.09 |
| Liabilities | 18.76 | 6.21 | 5.54 | 0.86 | 2.95 | 3.24 | 1.99 | 1.16 | 1.26 | 1.55 |
| Book Value | -12.22 | 5.02 | 5.88 | 9.90 | 14.13 | 6.68 | 2.74 | 3.98 | 1.49 | -0.46 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Brainstorm Cell Therapeutics Inc. |
| Country |
United States |
| Employees |
44 |
| CEO |
Chaim Lebovits |
Stock Information
| Ticker Symbol |
BCLI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BCLI |
Description
Brainstorm Cell Therapeutics, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company has a partnership with Catalent for the manufacture of NurOwn, an autologous cellular therapy. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.